Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18012440 | 0.77 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL7674661 | 0.72 | DUSP3 (0.40) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL23898662 | 0.70 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EGLALMNA | |
| SCHEMBL29636156 | 0.70 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EGLALMNA | |
| SCHEMBL9025371 | 0.70 | CYP1A2 (0.44) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL28546185 | 0.69 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1893844 | 0.68 | MAOA (0.45) | ALDH1A1KDM4EGLAMEN1KMT2A | |
| SCHEMBL16389423 | 0.67 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4EGLAMEN1 | |
| SCHEMBL29861263 | 0.67 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4EGLAMEN1 | |
| SCHEMBL9023887 | 0.67 | GLA (0.47) | ALDH1A1KDM4EGLALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746481-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152642-A1 | ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | MERCK SHARP & DOHME CORP. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2010012345-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-1874760-A1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | Merck Patent GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108487-A1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0347749-B1 | Pyrazoloacridone derivatives with anti-tumoral activity | KYOWA HAKKO KOGYO KK (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5079358-A | Humans; leukemia | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5079358-A | Humans; leukemia | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | ALDH1A1 2051/4885SMN1; SMN2 2874/4885NPC1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.